ONCOLOGY Vol 35, Issue 9

Takayuki Yoshino, MD, PhD provides perspective on key issues surrounding therapy selection in gastrointestinal cancers.

In an interview with ONCOLOGY®, Sandra Cuellar, PharmD, BCOP, FASHP, offers a comprehensive review of real-world treatment considerations of margetuximab as therapy for adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens with at least 1 being for metastatic disease.

“That’s the beauty of science. Anything can be intellectual.”

ONCOLOGY® co–editor-in-chief, Julie Vose, discusses how the COVID-19 pandemic has caused physician burnout and what may be done to prevent it.

This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.

Patients with colorectal cancer could benefit from the COLMATE platform as it allows for opportunities in clinical trial enrollment.

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.